Role of soluble epoxide hydrolase phosphatase activity in the metabolism of lysophosphatidic acids

Biochemical and Biophysical Research Communications

Volumn 419, Issue 4, 2012, Pages 796-800

  Morisseau, Christophe ^a   Schebb, Nils Helge ^a   Dong, Hua ^a   Ulu, Arzu ^a   Aronov, Pavel A ^a   Hammock, Bruce D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lysophosphatidic acid; Phosphatase; Soluble epoxide hydrolase

Indexed keywords

EPOXIDE HYDROLASE; EPOXIDE HYDROLASE PHOSPHATASE; LYSOPHOSPHATIDIC ACID; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; CYTOSOL; ENZYME ACTIVITY; ENZYME SUBSTRATE COMPLEX; HUMAN; LIPID HYDROLYSIS; MALE; MOUSE; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; PROTEIN FUNCTION;

EPOXIDE HYDROLASES; HUMANS; LYSOPHOSPHOLIPIDS; PHOSPHORIC ACID ESTERS; SMALL MOLECULE LIBRARIES; SOLUBILITY; SUBSTRATE SPECIFICITY;

PHOS;

EID: 84858746586     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2012.02.108     Document Type: Article

References (38)

1. Newman J.W., Morisseau C., Hammock B.D. Epoxide hydrolases: their roles and interactions with lipid metabolism. Prog. Lipid Res. 2005, 44:1-51.
2. De Taeye B.M., Morisseau C., Coyle J., et al. Expression and regulation of soluble epoxide hydrolase in adipose tissue. Obesity 2010, 18:489-498.
3. Gomez G.A., Morisseau C., Hammock B.D., et al. Structure of human soluble epoxide hydrolase reveals mechanistic interferences on bifunctional catalysis in epoxide and phosphate ester hydrolysis. Biochemistry 2004, 43:4716-4723.
4. Imig J.D., Hammock B.D. Soluble epoxide hydrolase as a therapeutic target for cardiovascular diseases. Nat. Rev. Drug. Discov. 2009, 8:794-805.
5. Iyer A., Fairlie D.P., Prins J.B., et al. Inflammatory lipid mediators in adipocyte function and obesity. Nat. Rev. Endocrinol. 2010, 6:71-82.
6. Ingraham R.H., Gless R.D., Lo H.Y. Soluble epoxide hydrolase inhibitors and their potential for treatment of multiple pathologic conditions. Curr. Med. Chem. 2011, 18:587-603.
7. Newman J.W., Morisseau C., Harris T.R., et al. The soluble epoxide hydrolase encoded by EPXH2 is a bifunctional enzyme with novel lipid phosphate phosphatase activity. Proc. Natl. Acad. Sci. USA 2003, 100:1558-1563.
8. Morisseau C., Inceoglu B., Schmelzer K., et al. Naturally occurring monoepoxides of eicosapentaenoic acid and docosahexaenoic acid are bioactive antihyperalgesic lipids. J. Lipid Res. 2010, 51:3481-3490.
9. Morisseau C., Goodrow M.H., Dowdy D., et al. Potent urea and carbamate inhibitors of soluble epoxide hydrolases. Proc. Natl. Acad. Sci. USA 1999, 96:8849-8854.
10. Imig J.D. Targeting epoxides for organ damage in hypertension. J. Cardiovasc. Pharmacol. 2010, 56:329-335.
11. Iliff J.J., Jia J., Nelson J., et al. Epoxyeicosanoid signaling in CNS function and disease. Prostaglandins Other Lipid Mediat. 2010, 91:68-84.
12. Luo P., Chang H.H., Zhou Y., et al. Inhibition or deletion of soluble epoxide hydrolase prevents hyperglycemia, promotes insulin secretion, and reduces islet apoptosis. J. Pharmacol. Exp. Ther. 2010, 334:430-438.
13. Iyer A., Kauter K., Alam M.A., et al. Pharmacological inhibition of soluble epoxide hydrolase ameliorates diet-induced metabolic syndrome in rats. Exp. Diabetes. Res. 2012, 2012:758614.
14. Luria A., Morisseau C., Tsai H.J., et al. Alteration in plasma testosterone levels in male mice lacking soluble epoxide hydrolase. Am. J. Physiol. Endocrinol. Metab. 2009, 297:E375-E383.
15. EnayetAllah A.E., Luria A., Luo B., et al. Opposite regulation of cholesterol levels by the phosphatase and hydrolase domains of soluble epoxide hydrolase. J. Biol. Chem. 2008, 283:36592-36598.
16. Oguro A., Sakamoto K., Suzuki S., et al. Contribution of hydrolase and phosphatase domains in soluble epoxide hydrolase to vascular endothelial growth factor expression and cell growth. Biol. Pharm. Bull. 2009, 32:1962-1967.
17. Keserü B., Barbosa-Sicard E., Schermuly R.T., et al. Hypoxia-induced pulmonary hypertension: comparison of soluble epoxide hydrolase deletion vs. inhibition. Cardiovasc. Res. 2010, 85:232-240.
18. Hou H.H., Hammock B.D., Su K.H., et al. N-terminal domain of soluble epoxide hydrolase negatively regulates the VEGF-mediated activation of endothelial nitric oxide synthase. Cardiovasc. Res. 2011, 93:120-129.
19. Fornage M., Boerwinkle E., Doris P.A., et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects. Circulation 2004, 109:335-339.
20. Ohtoshi K., Kaneto H., Node K., et al. Association of soluble epoxide hydrolase gene polymorphism with insulin resistance in type 2 diabetic patients. Biochem. Biophys. Res. Comm. 2005, 331:347-350.
21. Przybyla-Zawislak B.D., Srivastava P.K., Vásquez-Matías J., et al. Polymorphisms in human soluble epoxide hydrolase. Mol. Pharmacol. 2003, 64:482-490.
22. Srivastava P.K., Sharma V.K., Kalonia D.S., et al. Polymorphisms in human soluble epoxide hydrolase: effects on enzyme activity, enzyme stability, and quaternary structure. Arch. Biochem. Biophys. 2004, 427:164-169.
23. Fava C., Montagnana M., Danese E., et al. Homozygosity for the EPHX2 K55R polymorphism increases the long-term risk of ischemic stroke in men: a study in Swedes. Pharmacogenet. Genomics 2010, 20:94-103.
24. Tran K.L., Aronov P.A., Tanaka H., et al. Lipid Sulfates and sulfonates are allosteric competitive inhibitors of the N-terminal phosphatase activity of the mammalian soluble epoxide hydrolase. Biochemistry 2005, 44:12179-12187.
25. Enayetallah A.E., Grant D.F. Effects of human soluble epoxide hydrolase polymorphisms on isoprenoid phosphate hydrolysis. Biochem. Biophys. Res. Commun. 2006, 341:254-260.
26. Beetham J.K., Tian T., Hammock B.D. CDNA cloning and expression of a soluble epoxide hydrolase from human liver. Arch. Biochem. Biophys. 1993, 305:197-201.
27. Wixtrom R.N., Silva M.H., Hammock B.D. Affinity purification of cytosolic epoxide hydrolase using derivatized epoxy-activated Sepharose gels. Anal. Biochem. 1988, 169:71-80.
28. Jones P.D., Wolf N.M., Morisseau C., et al. Fluorescent substrates for soluble epoxide hydrolase and application to inhibition studies. Anal. Biochem. 2005, 343:66-75.
29. Schebb N.H., Falck D., Faber H., et al. Fast method for monitoring phospholipase A2 activity by liquid chromatography-electrospray ionization mass spectrometry. J. Chromatogr. A 2009, 1216:5249-5255.
30. Borhan B., Mebrahtu T., Nazarian S., et al. Improved radiolabeled substrates for soluble epoxide hydrolase. Anal. Biochem. 1995, 231:188-200.
31. Das A.K., Hajra A.K. Critical micellar concentrations of palmitoyl dehydroxyacetone phosphate and 1-palmitoyl-rac-glycerol 3-phosphate. J. Biol. Chem. 1992, 267:9731.
32. Sciorra V.A., Morris A.J. Roles for lipid phosphate phosphatases in regulation of cellular signaling. Biochim. Biophys. Acta 2002, 1582:45-51.
33. McDermott M.I., Sigal Y.J., Crump J.S., et al. Enzymatic analysis of lipid phosphate phosphatases. Methods 2006, 39:169-179.
34. Brindley D.N., Pilquil C., Sariahmetoglu M., et al. Phosphatidate degradation: phosphatidate phosphatases (lipins) and lipid phosphate phosphatases. Biochim. Biophys. Acta 2009, 1791:956-961.
35. Han G.S., Carman G.M. Characterization of the human LPIN1-encoded phosphatidate phosphatase isoforms. J. Biol. Chem. 2010, 285:14628-14638.
36. Lin M.E., Herr D.R., Chun J. Lysophosphatidic acid (LPA) receptors: signaling properties and disease relevance. Prostaglandins Other Lipid Mediat. 2010, 91:130-138.
37. Morris A.J., Panchatcharam M., Cheng H.Y., et al. Regulation of blood and vascular cell function by bioactive lysophospholipids. J. Thromb. Haemost. 2009, 7(Suppl. 1):38-43.
38. Tigyi G. Lipids: LPA activates TRPV1 and it hurts. Nat. Chem. Biol. 2011, 8:22-23.